IMCD Stock Analysis: IMCD | AS
Specialty Chemicals | AS, Netherlands | Market Cap: 4.790m EUR | 12M Return: -28.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.7M
EPS Trend: -2.4%
Rev. Trend: 84.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IMCD N.V. is a global specialty chemicals and ingredients distributor, marketing and selling a broad portfolio to customers across Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. Rather than manufacturing chemicals itself, the company acts as an intermediary between chemical producers and downstream formulators, serving end-markets such as advanced materials (adhesives, plastics, rubber, composites), personal care and beauty, food and nutrition, and home care and industrial cleaning. The product range spans additives, pigments, solvents, surfactants, emulsifiers, UV filters, and active ingredients, as well as lubricant components and oil, gas, and energy solutions for upstream, midstream, and downstream applications.
The company was founded in 1995 and is headquartered in Rotterdam, the Netherlands, and is classified within the Trading Companies & Distributors sub-industry. Specialty chemical distributors like IMCD typically earn margins by combining logistics, technical support, and formulation expertise, adding value beyond pure commodity resale by helping customers select and apply the right ingredients for their specific applications.
- Bolt-on acquisitions fuel consistent double-digit revenue growth across regions
- Specialty margins expand as high-value ingredients outpace commodity distribution volumes
- Personal care and pharma demand offsets softer industrial chemicals end markets
| Net Income: 217.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.24 > 1.0 |
| NWC/Revenue: 15.87% < 20% (prev 21.60%; Δ -5.74% < -1%) |
| CFO/TA 0.07 > 3% & CFO 322.3m > Net Income 217.6m |
| Net Debt (1.57b) to EBITDA (521.0m): 3.01 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.1m) vs 12m ago 3.54% < -2% |
| Gross Margin: 17.72% > 18% (prev 18.43%; Δ -0.71% > 0.5%) |
| Asset Turnover: 100.7% > 50% (prev 97.10%; Δ 3.62% > 0%) |
| Interest Coverage Ratio: 4.83 > 6 (EBIT TTM 378.1m / Interest Expense TTM 78.2m) |
| A: 0.16 (Total Current Assets 1.80b - Total Current Liabilities 1.03b) / Total Assets 4.64b |
| B: 0.22 (Retained Earnings 1.00b / Total Assets 4.64b) |
| C: 0.08 (EBIT TTM 378.1m / Avg Total Assets 4.76b) |
| D: 0.79 (Book Value of Equity 2.04b / Total Liabilities 2.59b) |
| Altman-Z'' = 3.14 = A |
| DSRI: 1.12 (Receivables 853.7m/754.5m, Revenue 4.79b/4.74b) |
| GMI: 1.04 (GM 18.43% / 17.72%) |
| AQI: 1.06 (AQ_t 0.58 / AQ_t-1 0.55) |
| SGI: 1.01 (Revenue 4.79b / 4.74b) |
| TATA: -0.02 (NI 217.6m - CFO 322.3m) / TA 4.64b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at EUR 79.72 with a total of 224,586 shares traded. Over the past week, the price has changed by -2.71%, over one month by -11.60%, over three months by -8.56% and over the past year by -28.88%.
Current recommended Stop Loss: 76.60 (which is 3.9% or 1.3 ATR below the current price).
IMCD has no consensus analysts rating.
P/E Trailing = 22.0489
P/E Forward = 13.5135
P/S = 0.9969
P/B = 2.3701
Revenue TTM = 4.79b EUR
EBIT TTM = 378.1m EUR
EBITDA TTM = 521.0m EUR
Long Term Debt = 1.29b EUR (from longTermDebt, last quarter)
Short Term Debt = 325.0m EUR (from shortTermDebt, last quarter)
Debt = 1.81b EUR (from shortLongTermDebtTotal, last quarter) + Leases 104.2m
Net Debt = 1.57b EUR (calculated: Debt 1.81b - CCE 238.6m)
Enterprise Value = 6.36b EUR (4.79b + Debt 1.81b - CCE 238.6m)
Interest Coverage Ratio = 4.83 (Ebit TTM 378.1m / Interest Expense TTM 78.2m)
EV/FCF = 20.56x (Enterprise Value 6.36b / FCF TTM 309.2m)
FCF Yield = 4.86% (FCF TTM 309.2m / Enterprise Value 6.36b)
FCF Margin = 6.45% (FCF TTM 309.2m / Revenue TTM 4.79b)
Net Margin = 4.54% (Net Income TTM 217.6m / Revenue TTM 4.79b)
Gross Margin = 17.72% ((Revenue TTM 4.79b - Cost of Revenue TTM 3.94b) / Revenue TTM)
Gross Margin QoQ = 8.77% (prev 26.02%)
Tobins Q-Ratio = 1.37 (Enterprise Value 6.36b / Total Assets 4.64b)
Interest Expense / Debt = 4.33% (Interest Expense 78.2m / Debt 1.81b)
Taxrate = 25.29% (73.6m / 291.1m)
NOPAT = 282.5m (EBIT 378.1m * (1 - 25.29%))
Current Ratio = 1.73 (Total Current Assets 1.80b / Total Current Liabilities 1.03b)
Debt / Equity = 0.89 (Debt 1.81b / totalStockholderEquity, last quarter 2.04b)
Debt / EBITDA = 3.01 (Net Debt 1.57b / EBITDA 521.0m)
Debt / FCF = 5.07 (Net Debt 1.57b / FCF TTM 309.2m)
Total Stockholder Equity = 1.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.57% (Net Income 217.6m / Total Assets 4.64b)
RoE = 10.91% (Net Income TTM 217.6m / Total Stockholder Equity 1.99b)
RoCE = 11.51% (EBIT 378.1m / Capital Employed (Equity 1.99b + L.T.Debt 1.29b))
RoIC = 7.66% (NOPAT 282.5m / Invested Capital 3.69b)
WACC = 5.58% (E(4.79b)/V(6.60b) * Re(6.46%) + D(1.81b)/V(6.60b) * Rd(4.33%) * (1-Tc(0.25)))
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 40.45 | Cagr: 1.54%
[DCF] Terminal Value 77.97% ; FCFF base≈291.6m ; Y1≈334.3m ; Y5≈492.0m
[DCF] Fair Price = 98.83 (EV 7.40b - Net Debt 1.57b = Equity 5.83b / Shares 59.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -2.45 | EPS CAGR: -0.19% | SUE: N/A | # QB: 0
Revenue Correlation: 84.65 | Revenue CAGR: 3.05% | SUE: -0.07 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=5.78 | Chg30d=-1.54% | Revisions=+33% | GrowthEPS=+11.5% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=6.26 | Chg30d=+0.07% | Revisions=+33% | GrowthEPS=+8.2% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: +33%